共 50 条
Simultaneous Detection of Prolactin and Growth Hormone Using a Dual-label Time-resolved Fluorescence Immunoassay
被引:0
|作者:
Zhong, Shuhai
[1
]
Liang, Huankun
[2
]
Peng, Fenglan
[3
]
Lu, Yanhong
[2
]
Liu, Tiancai
[4
]
Kulchytski, Uladzimir
[5
]
Dong, Wenqi
[6
]
机构:
[1] Guangzhou Youdi Biotechnol Co Ltd, Guangzhou 510663, Peoples R China
[2] Jinan Laide Biotechnol Co Ltd, Jinan 271100, Peoples R China
[3] Taian Disabled Soldiers Hosp Shandong Prov, Tai An 271099, Peoples R China
[4] Southern Med Univ, Sch Lab Med & Biotechnol, Guangzhou 510515, Guangdong, Peoples R China
[5] Natl Acad Sci Belarus, Inst Physiol, Minsk 220072, BELARUS
[6] Guangzhou Zhenda Biopharmaceut Technol Co Ltd, 3 Juquan Rd, Guangzhou 510663, Peoples R China
关键词:
Prolactin;
Growth hormone;
Time-resolved fluorescence immunoassay;
Serum;
CANCER;
DIAGNOSIS;
D O I:
10.1007/s10895-023-03395-w
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
Prolactin (PRL) and growth hormone (GH) are two important hormones secreted by the pituitary gland, and their abnormal levels are often related to disease status. This study aimed to establish a new dual-label time-resolved fluorescence immunoassay (TRFIA) to quantitatively measure PRL and GH levels in serum. A sandwich TRFIA was optimized and established: anti-PRL/GH antibodies immobilized on 96-well plates captured PRL/GH and then banded together with anti-PRL/GH paired antibodies labeled with europium(III) (Eu3+)/samarium(III) (Sm3+) chelates. Finally, a time-resolved analyzer measured the Eu3+/Sm3+ fluorescence values. Clinical serum samples were used to evaluate the detection performance of this method. The sensitivities of this dual-label TRFIA were 0.35 ng/mL and 0.45 ng/mL, respectively, and the detection range was between 0.1 and 1000 ng/mL. All the cross-reactivities were lower than 1.07%. The intra-assay and interassay coefficients of variation were 2.18-7.85% and 2.25-7.30%, respectively. Compared with the registered TRFIA kits, a high Pearson coefficient (r = 0.9626 and 0.9675) was observed. This dual-label TRFIA has high sensitivity, accuracy and specificity with good clinical detection performance, representing a suitable alternative to existing methods for determining PRL and GH levels, and is expected to be used in the clinic in the future.
引用
收藏
页码:1417 / 1422
页数:6
相关论文